MP Biomedicals Submits BLA for FDA Approval of HTLV

MP Biomedicals, LLC, a company that offers a comprehensive line of life science products, said that it has already submitted a Biologic License Application (BLA) needed for FDA approval of the HTLV Blot 2.4 confirmatory testing and viral typing which will be used on blood donors and patients.

As quoted in the press release:

An important aspect of the HTLV Blot 2.4 is the incorporation of unique recombinant proteins from the envelopes of both HTLV-I and HTLV-II viruses. This feature greatly enhances sensitivity and specificity, providing clinical and donor labs with reliable results for both confirmation and differentiation between HTLV-I and HTLV-II infections.

Click here to read the full MP Biomedicals, LLC press release.